Lisavanbulin (dihydrochloride)

Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma^[1][2][3][4]. In Vitro:Lisavanbulin dihydrochloride (0-50 nM) has a cytostatic and cytolytic effect on SB28 cells with an IC₅₀ of 5.5 nM^[4].
Lisavanbulin dihydrochloride (0-10 nM) increases the extracellular release of high mobility group box (HMGB1) in SB28 cells^[4]. In Vivo:Lisavanbulin dihydrochloride (25 mg/kg, p.o., 25 d) shows a clear reduction in tumor size in SB28 glioma implanted orthotopic C57BL/6J mice^[4].